<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on April 22, 2026 at 4:37 PM by All in One SEO v4.9.6.2 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://cgxpwire.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>cGxP.wire</title>
		<link><![CDATA[https://cgxpwire.com]]></link>
		<description><![CDATA[cGxP.wire]]></description>
		<lastBuildDate><![CDATA[Wed, 22 Apr 2026 09:21:24 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://cgxpwire.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/nuvation-bio-strengthens-oncology-pipeline-with-ibtrozi-and-safusidenib-advances/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/nuvation-bio-strengthens-oncology-pipeline-with-ibtrozi-and-safusidenib-advances/]]></link>
			<title>Nuvation Bio Strengthens Oncology Pipeline with IBTROZI and Safusidenib Advances</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 09:21:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/akeso-cadonilimab-combo-shows-strong-survival-in-pancreatic-cancer/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/akeso-cadonilimab-combo-shows-strong-survival-in-pancreatic-cancer/]]></link>
			<title>Akeso Cadonilimab Combo Shows Strong Survival in Pancreatic Cancer</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 09:01:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/insilico-medicine-launches-longevity-board-for-ai-drug-discovery/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/insilico-medicine-launches-longevity-board-for-ai-drug-discovery/]]></link>
			<title>Insilico Medicine Launches Longevity Board for AI Drug Discovery</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 08:46:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/monopar-alxn1840-phase-3-data-improves-wilson-disease-outcomes/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/monopar-alxn1840-phase-3-data-improves-wilson-disease-outcomes/]]></link>
			<title>Monopar ALXN1840 Phase 3 Data Improves Wilson Disease Outcomes</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 08:38:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/biocon-gains-health-canada-nod-for-denosumab-biosimilars/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/biocon-gains-health-canada-nod-for-denosumab-biosimilars/]]></link>
			<title>Biocon Gains Health Canada Nod for Denosumab Biosimilars</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 08:22:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/vapotherm-gains-fda-clearance-for-all-patient-circuit-device/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/vapotherm-gains-fda-clearance-for-all-patient-circuit-device/]]></link>
			<title>Vapotherm Gains FDA Clearance for All Patient Circuit Device</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 07:17:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/polaryx-therapeutics-secures-fda-fast-track-for-plx-200-in-rare-diseases/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/polaryx-therapeutics-secures-fda-fast-track-for-plx-200-in-rare-diseases/]]></link>
			<title>Polaryx Therapeutics Secures FDA Fast Track for PLX-200 in Rare Diseases</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 07:06:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/karyopharm-sentry-trial-advances-myelofibrosis-treatment/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/karyopharm-sentry-trial-advances-myelofibrosis-treatment/]]></link>
			<title>Karyopharm SENTRY Trial Advances Myelofibrosis Treatment</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 06:46:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/cristcot-nda-accepted-for-nghca-in-ulcerative-colitis/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/cristcot-nda-accepted-for-nghca-in-ulcerative-colitis/]]></link>
			<title>Cristcot NDA Accepted for ngHCA in Ulcerative Colitis</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 06:00:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/castle-biosciences-decisiondx-melanoma-improves-risk-prediction/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/castle-biosciences-decisiondx-melanoma-improves-risk-prediction/]]></link>
			<title>Castle Biosciences DecisionDx Melanoma Improves Risk Prediction</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 05:52:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/mergers-acquisitions/dark-horse-consulting-expands-asia-with-cj-partners-deal/]]></guid>
			<link><![CDATA[https://cgxpwire.com/mergers-acquisitions/dark-horse-consulting-expands-asia-with-cj-partners-deal/]]></link>
			<title>Dark Horse Consulting Expands Asia with CJ PARTNERS Deal</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 05:47:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/cellectar-biosciences-showcases-iopofosine-data-at-asco/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/cellectar-biosciences-showcases-iopofosine-data-at-asco/]]></link>
			<title>Cellectar Biosciences Showcases Iopofosine Data at ASCO</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 05:43:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/ideaya-biosciences-darovasertib-combo-advances-uveal-melanoma-care/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/ideaya-biosciences-darovasertib-combo-advances-uveal-melanoma-care/]]></link>
			<title>IDEAYA Biosciences Darovasertib Combo Advances Uveal Melanoma Care</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 05:34:40 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/nuvalent-alkove-1-data-boosts-nsclc-targeted-therapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/nuvalent-alkove-1-data-boosts-nsclc-targeted-therapy/]]></link>
			<title>Nuvalent ALKOVE-1 Data Boosts NSCLC Targeted Therapy</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 05:30:43 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/mergers-acquisitions/biogen-tj-biopharma-felzartamab-global-rights-deal/]]></guid>
			<link><![CDATA[https://cgxpwire.com/mergers-acquisitions/biogen-tj-biopharma-felzartamab-global-rights-deal/]]></link>
			<title>Biogen &amp; TJ Biopharma Felzartamab Global Rights Deal</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 05:25:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/cardiff-oncology-onvansertib-mcrc-data-at-asco-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/cardiff-oncology-onvansertib-mcrc-data-at-asco-2026/]]></link>
			<title>Cardiff Oncology Onvansertib mCRC Data at ASCO 2026</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 05:17:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/roche-enspryng-shows-mogad-clinical-benefit-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/roche-enspryng-shows-mogad-clinical-benefit-data/]]></link>
			<title>Roche ENSPRYNG Shows MOGAD Clinical Benefit Data</title>
			<pubDate><![CDATA[Wed, 22 Apr 2026 04:56:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/technology/oracle-health-drives-interoperability-digital-check-in/]]></guid>
			<link><![CDATA[https://cgxpwire.com/technology/oracle-health-drives-interoperability-digital-check-in/]]></link>
			<title>Oracle Health Drives Interoperability, Digital Check-In</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 12:11:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/rznomics-rz-001-shows-strong-hcc-clinical-data-aacr/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/rznomics-rz-001-shows-strong-hcc-clinical-data-aacr/]]></link>
			<title>Rznomics RZ-001 Shows Strong HCC Clinical Data AACR</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 09:40:35 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/enara-bio-showcases-ena101-cancer-immunotherapy-at-aacr/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/enara-bio-showcases-ena101-cancer-immunotherapy-at-aacr/]]></link>
			<title>Enara Bio Showcases ENA101 Cancer Immunotherapy at AACR</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 09:28:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/astellas-and-pfizer-gain-fda-priority-review-for-padcev-combo/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/astellas-and-pfizer-gain-fda-priority-review-for-padcev-combo/]]></link>
			<title>Astellas and Pfizer Gain FDA Priority Review for PADCEV Combo</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 08:17:08 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/nektar-rezpegaldesleukin-shows-52-week-alopecia-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/nektar-rezpegaldesleukin-shows-52-week-alopecia-results/]]></link>
			<title>Nektar Rezpegaldesleukin Shows 52-Week Alopecia Results</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 08:01:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/verismo-synkir-110-shows-phase-1-safety-in-solid-tumors/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/verismo-synkir-110-shows-phase-1-safety-in-solid-tumors/]]></link>
			<title>Verismo SynKIR-110 Shows Phase 1 Safety in Solid Tumors</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 06:51:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/nanostics-ai-claritydx-prostate-study-improves-cancer-detection/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/nanostics-ai-claritydx-prostate-study-improves-cancer-detection/]]></link>
			<title>Nanostics AI ClarityDX Prostate Study Improves Cancer Detection</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 06:38:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/veterinary/ema-recommends-first-rna-based-veterinary-vaccine-in-eu/]]></guid>
			<link><![CDATA[https://cgxpwire.com/veterinary/ema-recommends-first-rna-based-veterinary-vaccine-in-eu/]]></link>
			<title>EMA Recommends First RNA-Based Veterinary Vaccine in EU</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 06:29:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/mergers-acquisitions/ucb-acquires-neurona-to-advance-epilepsy-cell-therapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/mergers-acquisitions/ucb-acquires-neurona-to-advance-epilepsy-cell-therapy/]]></link>
			<title>UCB Acquires Neurona to Advance Epilepsy Cell Therapy</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 05:31:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/astrazeneca-reports-phase-iii-success-for-tozorakimab-in-copd/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/astrazeneca-reports-phase-iii-success-for-tozorakimab-in-copd/]]></link>
			<title>AstraZeneca Reports Phase III Success for Tozorakimab in COPD</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 05:22:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/cmp-pharma-introduces-alcohol-free-norliqva-for-pediatrics/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/cmp-pharma-introduces-alcohol-free-norliqva-for-pediatrics/]]></link>
			<title>CMP Pharma Introduces Alcohol-Free Norliqva for Pediatrics</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 05:17:39 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/mergers-acquisitions/quidelortho-acquires-lex-to-boost-rapid-pcr-diagnostics/]]></guid>
			<link><![CDATA[https://cgxpwire.com/mergers-acquisitions/quidelortho-acquires-lex-to-boost-rapid-pcr-diagnostics/]]></link>
			<title>QuidelOrtho Acquires LEX to Boost Rapid PCR Diagnostics</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 05:10:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/technology/texas-biomed-advances-ai-tools-to-transform-drug-testing/]]></guid>
			<link><![CDATA[https://cgxpwire.com/technology/texas-biomed-advances-ai-tools-to-transform-drug-testing/]]></link>
			<title>Texas Biomed Advances AI Tools to Transform Drug Testing</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 05:00:22 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/technology/boehringer-ingelheim-expands-ai-innovation-hub-in-uk/]]></guid>
			<link><![CDATA[https://cgxpwire.com/technology/boehringer-ingelheim-expands-ai-innovation-hub-in-uk/]]></link>
			<title>Boehringer Ingelheim Expands AI Innovation Hub in UK</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 04:53:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/mergers-acquisitions/eli-lilly-to-acquire-kelonia-for-in-vivo-car-t-breakthrough/]]></guid>
			<link><![CDATA[https://cgxpwire.com/mergers-acquisitions/eli-lilly-to-acquire-kelonia-for-in-vivo-car-t-breakthrough/]]></link>
			<title>Eli Lilly to Acquire Kelonia for In Vivo CAR-T Breakthrough</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 04:47:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/novo-nordisk-reports-etavopivat-phase-3-breakthrough/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/novo-nordisk-reports-etavopivat-phase-3-breakthrough/]]></link>
			<title>Novo Nordisk Reports Etavopivat Phase 3 Breakthrough</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 04:36:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/revolution-medicines-reports-breakthrough-zoldonrasib-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/revolution-medicines-reports-breakthrough-zoldonrasib-data/]]></link>
			<title>Revolution Medicines Reports Breakthrough Zoldonrasib Data</title>
			<pubDate><![CDATA[Tue, 21 Apr 2026 04:30:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/synthetic-design-lab-unveils-logic-gated-adc-platform/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/synthetic-design-lab-unveils-logic-gated-adc-platform/]]></link>
			<title>Synthetic Design Lab Unveils Logic-Gated ADC Platform</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 10:14:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/monopar-reports-phase-3-alxn1840-data-at-aan-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/monopar-reports-phase-3-alxn1840-data-at-aan-2026/]]></link>
			<title>Monopar Reports Phase 3 ALXN1840 Data at AAN 2026</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 10:03:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/epibiologics-doses-first-patient-in-epi-326-phase-1-study/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/epibiologics-doses-first-patient-in-epi-326-phase-1-study/]]></link>
			<title>EpiBiologics Doses First Patient in EPI-326 Phase 1 Study</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 09:50:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/nanobiotix-reports-nanoprimer-breakthrough-at-aacr-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/nanobiotix-reports-nanoprimer-breakthrough-at-aacr-2026/]]></link>
			<title>Nanobiotix Reports Nanoprimer Breakthrough at AACR 2026</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 09:25:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/philips-verida-ai-spectral-ct-wins-fda-510k-clearance/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/philips-verida-ai-spectral-ct-wins-fda-510k-clearance/]]></link>
			<title>Philips Verida AI Spectral CT Wins FDA 510(k) Clearance</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 07:14:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/leo-pharma-wins-china-approval-for-enstilar-psoriasis-drug/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/leo-pharma-wins-china-approval-for-enstilar-psoriasis-drug/]]></link>
			<title>LEO Pharma Wins China Approval for Enstilar Psoriasis Drug</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 07:09:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/abbott-cancerguard-advances-multi-cancer-detection-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/abbott-cancerguard-advances-multi-cancer-detection-data/]]></link>
			<title>Abbott Cancerguard Advances Multi-Cancer Detection Data</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 07:03:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/piramal-ajinomoto-partner-to-boost-adc-manufacturing/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/piramal-ajinomoto-partner-to-boost-adc-manufacturing/]]></link>
			<title>Piramal, Ajinomoto Partner to Boost ADC Manufacturing</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 06:52:43 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/intelligent-bio-advances-fda-510k-with-cybersecurity/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/intelligent-bio-advances-fda-510k-with-cybersecurity/]]></link>
			<title>Intelligent Bio Advances FDA 510(k) with Cybersecurity</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 06:35:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/lilly-foundayo-shows-strong-phase-3-diabetes-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/lilly-foundayo-shows-strong-phase-3-diabetes-results/]]></link>
			<title>Lilly Foundayo Shows Strong Phase 3 Diabetes Results</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 06:25:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/mergers-acquisitions/gilead-secures-approvals-for-arcellx-acquisition-deal/]]></guid>
			<link><![CDATA[https://cgxpwire.com/mergers-acquisitions/gilead-secures-approvals-for-arcellx-acquisition-deal/]]></link>
			<title>Gilead Secures Approvals for Arcellx Acquisition Deal</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 06:19:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/corify-care-gains-fda-clearance-for-acorys-4d-mapping/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/corify-care-gains-fda-clearance-for-acorys-4d-mapping/]]></link>
			<title>Corify Care Gains FDA Clearance for ACORYS 4D Mapping</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 06:09:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/xodus-medical-gains-fda-clearance-for-hot-pink-pad/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/xodus-medical-gains-fda-clearance-for-hot-pink-pad/]]></link>
			<title>Xodus Medical Gains FDA Clearance for Hot Pink Pad</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 05:28:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/kura-oncology-shows-strong-rcc-data-with-combo-therapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/kura-oncology-shows-strong-rcc-data-with-combo-therapy/]]></link>
			<title>Kura Oncology Shows Strong RCC Data with Combo Therapy</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 05:17:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/marengo-reports-phase-2-breast-cancer-data-at-aacr/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/marengo-reports-phase-2-breast-cancer-data-at-aacr/]]></link>
			<title>Marengo Reports Phase 2 Breast Cancer Data at AACR</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 05:08:37 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/merck-enflonsia-approved-in-eu-for-infant-rsv-protection/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/merck-enflonsia-approved-in-eu-for-infant-rsv-protection/]]></link>
			<title>Merck ENFLONSIA Approved in EU for Infant RSV Protection</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 04:58:17 +0000]]></pubDate>
		</item>
				</channel>
</rss>
